X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4732) 4732
Publication (352) 352
Book Review (61) 61
Book Chapter (15) 15
Newsletter (13) 13
Magazine Article (10) 10
Book / eBook (8) 8
Conference Proceeding (8) 8
Dissertation (2) 2
Newspaper Article (2) 2
Trade Publication Article (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3601) 3601
male (2471) 2471
cardiotonic agents - therapeutic use (2222) 2222
index medicus (2170) 2170
female (1880) 1880
animals (1503) 1503
cardiac & cardiovascular systems (1473) 1473
middle aged (1343) 1343
cardiotonic agents - pharmacology (1207) 1207
aged (1155) 1155
cardiotonic agents - adverse effects (1038) 1038
heart failure - drug therapy (997) 997
cardiotonic agents - administration & dosage (962) 962
cardiotonic agents (754) 754
heart failure (753) 753
pharmacology & pharmacy (722) 722
adult (682) 682
treatment outcome (679) 679
rats (646) 646
dobutamine (539) 539
heart (521) 521
mortality (504) 504
risk factors (489) 489
hemodynamics - drug effects (458) 458
heart failure - physiopathology (450) 450
cardiac glycosides (426) 426
time factors (392) 392
cardiology (389) 389
echocardiography (374) 374
prospective studies (353) 353
surgery (349) 349
care and treatment (347) 347
analysis (341) 341
dose-response relationship, drug (330) 330
heart rate - drug effects (321) 321
oxidative stress (320) 320
health aspects (310) 310
cardiovascular (308) 308
heart-failure (305) 305
heart - drug effects (301) 301
cardiac patients (293) 293
myocardium - metabolism (293) 293
electrocardiography (288) 288
medicine & public health (285) 285
retrospective studies (285) 285
drug therapy (281) 281
aged, 80 and over (280) 280
ischemia (279) 279
mice (273) 273
research (269) 269
myocardial contraction - drug effects (266) 266
prognosis (263) 263
blood pressure - drug effects (258) 258
myocardium - pathology (252) 252
rats, sprague-dawley (252) 252
apoptosis (246) 246
disease models, animal (245) 245
anesthesiology (242) 242
vasodilator agents - therapeutic use (242) 242
infusions, intravenous (241) 241
heart failure - mortality (239) 239
pyridazines - therapeutic use (236) 236
rats, wistar (233) 233
acute myocardial-infarction (226) 226
medicine, general & internal (224) 224
abridged index medicus (222) 222
therapy (221) 221
digoxin (220) 220
follow-up studies (214) 214
myocardial-infarction (211) 211
peripheral vascular disease (210) 210
drug therapy, combination (208) 208
double-blind method (207) 207
milrinone (206) 206
myocytes, cardiac - drug effects (206) 206
hemodynamics (202) 202
hydrazones - therapeutic use (201) 201
heart attacks (198) 198
myocardial infarction (198) 198
physiological aspects (192) 192
heart diseases (191) 191
article (187) 187
ventricular function, left - drug effects (186) 186
levosimendan (185) 185
respiratory system (184) 184
risk assessment (182) 182
cardiopulmonary bypass (180) 180
adolescent (178) 178
oxidative stress - drug effects (178) 178
cardiomyopathy (177) 177
biochemistry & molecular biology (176) 176
child (175) 175
pediatrics (174) 174
digoxin - therapeutic use (173) 173
dobutamine - adverse effects (171) 171
hypertension (171) 171
rodents (171) 171
cardiovascular disease (169) 169
physiology (168) 168
cell biology (167) 167
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4493) 4493
German (70) 70
French (38) 38
Russian (33) 33
Spanish (31) 31
Japanese (21) 21
Italian (13) 13
Chinese (10) 10
Dutch (9) 9
Polish (9) 9
Portuguese (8) 8
Czech (7) 7
Hungarian (5) 5
Norwegian (4) 4
Turkish (4) 4
Danish (3) 3
Romanian (2) 2
Ukrainian (2) 2
Croatian (1) 1
Finnish (1) 1
Hebrew (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Antioxidants & Redox Signaling, ISSN 1523-0864, 03/2013, Volume 18, Issue 8, pp. 899 - 929
Significance: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their clinical usefulness is... 
Forum Review Articles | DOXORUBICIN-INDUCED CARDIOTOXICITY | ADVANCED BREAST-CANCER | SPONTANEOUSLY HYPERTENSIVE-RATS | MANGANESE SUPEROXIDE-DISMUTASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ADRIAMYCIN-INDUCED CARDIOMYOPATHY | ACUTE LYMPHOBLASTIC-LEUKEMIA | ENDOCRINOLOGY & METABOLISM | SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE | MITOCHONDRIAL CALCIUM HOMEOSTASIS | CONGESTIVE-HEART-FAILURE | FREE-RADICAL FORMATION | Anthracyclines - adverse effects | Reactive Oxygen Species - metabolism | Antioxidants - chemistry | Oxidative Stress | Humans | Metals - adverse effects | Razoxane - pharmacology | Anthracyclines - pharmacology | Antineoplastic Agents - adverse effects | Cardiotonic Agents - adverse effects | Myocardium - metabolism | Antineoplastic Agents - pharmacology | Razoxane - chemistry | Chelating Agents - adverse effects | Anthracyclines - chemistry | Oxidation-Reduction | Signal Transduction | Chelating Agents - chemistry | Cardiotonic Agents - chemistry | Antioxidants - pharmacology | Cardiotonic Agents - pharmacology | Chelating Agents - pharmacology | Antineoplastic Agents - chemistry | Razoxane - adverse effects | Heart - drug effects | Complications and side effects | Oxidative stress | Anthracyclines | Oxidation-reduction reaction | Chemical reactions | Dosage and administration | Research | Index Medicus | Forum Review
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 09/2013, Volume 33, Issue 9, pp. 2252 - 2260
OBJECTIVE—Experimental evidence suggests that exenatide, a glucagon-like peptide 1 receptor analogue, has significant cardiovascular protective effects in... 
magnetic resonance imaging | percutaneous coronary intervention | reperfusion injury | myocardial infarction | exenatide | SURVIVAL | RAT | HEART-FAILURE | SIZE | ISCHEMIA | GLUCAGON-LIKE PEPTIDE-1 | PERIPHERAL VASCULAR DISEASE | DYSFUNCTION | HEMATOLOGY | STRAIN | OCCLUSION | Myocardial Infarction - blood | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Myocardial Contraction - drug effects | Male | Peptides - administration & dosage | Troponin I - blood | Cardiotonic Agents - therapeutic use | Myocardial Infarction - therapy | Hypoglycemic Agents - administration & dosage | Time Factors | Cardiotonic Agents - adverse effects | Injections, Subcutaneous | Myocardial Infarction - pathology | Echocardiography, Doppler | Venoms - administration & dosage | Female | Myocardial Infarction - physiopathology | Republic of Korea | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Venoms - adverse effects | Ventricular Function, Left - drug effects | Proportional Hazards Models | Stroke Volume - drug effects | Myocardium - pathology | Treatment Outcome | Biomarkers - blood | Chi-Square Distribution | Magnetic Resonance Imaging | Myocardium - enzymology | Cardiotonic Agents - administration & dosage | Venoms - therapeutic use | Creatine Kinase, MB Form - blood | Aged | Hypoglycemic Agents - adverse effects | Percutaneous Coronary Intervention - adverse effects | Peptides - adverse effects | Peptides - therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 21, pp. 2021 - 2031
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 21, pp. 2032 - 2042
Journal Article
Journal Article